Revolutionize Adnexal Mass Management with OvaSuiteSM

Empower your health system with our OvaSuite portfolio - the cutting-edge solution for precise ovarian cancer risk assessment.

Our OvaSuite Portfolio

Aspira_OVAWatch(R) logo 1

Planned for Clinical Management

  • For adnexal masses initially evaluated as indeterminate or benign
  • Negative Predictive Value of over 99%1
  • Longitudinal monitoring feature to help providers track risk over time
Ova1 plus

Planned for Surgical Management

  • For adnexal masses that are planned for surgery
  • Ova1® has a greater than 96% sensitivity with clinical assessment2
  • Biomarkers (including CA-125), menopausal status, and ultrasound for a personalized risk score

Ova1Plus is a reflex process: Ova1® is performed3 first. If an intermediate risk is detected, Overa® is automatically performed.

Why Choose OvaSuite?

Apply Objective Risk Scores to the Subjective Aspects of Imaging

-Data shows that up to 50% of adnexal masses are considered indeterminate on imaging6

-Discordance in ultrasound interpretation is common6

-Utilize OvaSuite tests as additional tools for objective risk assessment

Drive Health Equity

-Help improve the equity of adnexal mass assessment and care in non-white women

-Bridge the gap in ethnic disparities, particularly for African American patients

-In a peer-reviewed study, Ova1 demonstrated superior performance to CA-125 alone in the African American population5

Optimize Gynecologic Oncology Access

-Optimize referrals based on risk of malignancy, reducing wait times for high-risk patients with Ova1

-Manage low-risk patients closer to home, improving convenience, patient centric care, and accessibility with OvaWatch

Pursue Ovary Preservation

-OvaWatch can potentially avoid premature surgeries, resulting in possibly lower overall cost of care for adnexal mass management

Improve Patient Retention and Experience

-Triage more precisely and retain surgical patients within your practice with Ova1

-Ease patient stress by avoiding potentially unnecessary oncologist referrals

Potential Surgical Reduction

-In a peer-reviewed study, Ova1 demonstrated an up to 77% and 59% reduction in surgeries for premenopausal and asymptomatic women, respectively4

-Use Ova1 to make informed decisions about delaying or avoiding surgery

Effective Surgical Prioritization

-Reduce overall cost of care through the avoidance of surgery for low-risk patients with OvaWatch

In the United States, there are approximately 9.1 surgeries per malignancy for adnexal masses, compared to just 2.3-5.9 in European centers. It's time to enhance our preoperative assessments and improve patient outcomes.7

Contact us to see OvaSuite in action at your health system.

Explore How Ova1Plus Transforms Ovarian Cancer Risk Assessment

Read real patient scenarios where Ova1Plus provided critical insights, helping to assess ovarian cancer risk and individualized treatment decisions.

Enhance & Empower Your System’s Efficiency with
Ova-Implement & Aspira Synergy Options

Integrate seamlessly into your existing workflows

Receive comprehensive support and training from our expert team

Access ongoing education and latest research

Expand your existing test menu utilizing your existing chemistry analyzer

Generate revenue and utilize analyzer capacity with your existing chemistry analyzer

Leverage Aspira's data analysis and report distribution services

Covered by most major payers (Ova1: CPT 81503)

Join Us in Advancing Ovarian Cancer Research

Participate in our ongoing clinical studies to shape the future of women's health. We can partner with you for opportunities in both prospective and potential retrospective studies.

Contact Us

Partner with Aspira Women's Health in various capacities.

Health Systems

Laboratories

Clinical Studies

Payers

Get In Touch

PRECAUTION:
OVAWATCH IS INTENDED FOR USE AS A NON-INVASIVE TEST TO ASSESS THE RISK OF OVARIAN CANCER FOR WOMEN WITH ADNEXAL MASSES, EVALUATED BY INITIAL CLINICAL ASSESSMENT (ICA) AS INDETERMINATE OR BENIGN. IN CONJUNCTION WITH IMAGING (ULTRASOUND AND/OR CT) AND CLINICAL ASSESSMENT, THIS TEST WILL SUPPORT PHYSICIANS IN MAKING INFORMED CLINICAL DECISIONS IN THE MANAGEMENT OF WOMEN WITH ADNEXAL MASSES. THE TEST IS NOT INTENDED AS A SCREENING TEST OR A STAND-ALONE DIAGNOSTIC ASSAY.

OVA1 AND OVERA SHOULD NOT BE USED WITHOUT AN INDEPENDENT CLINICAL AND IMAGING EVALUATION AND IS NOT INTENDED TO BE A SCREENING TEST OR TO DETERMINE WHETHER A PATIENT SHOULD PROCEED TO SURGERY. INCORRECT USE CARRIES THE RISK OF UNNECESSARY TESTING, SURGERY, AND/OR DELAYED DIAGNOSIS.

*In cases of an intermediate Ova1® result, the FDA-cleared Overa® reflex is performed to increase specificity